Volatile Week, but Green? Click to watch the new Podcast.

$1.64 (-9.39%)

Volume: 4.316k

Closed: Jul 05, 2022

Hollow Logo Score: -7.342

Celyad SA Stock Forecast

$1.64 (-9.39%)

Volume: 4.316k

Closed: Jul 05, 2022

Score Hollow Logo -7.342

Celyad SA Company Profile

Rue Edouard Belin 12

Mont-Saint-Guibert 1435

32 1 039 41 00


Industry: Biotechnology

Sector: Healthcare

Celyad SA


Celyad SA, a clinical-stage biopharmaceutical company, focuses on engineered cell therapy treatments. It develops therapeutic therapies for the treatment of unmet medical needs in cardiology and oncology. The company offers C-Cure, an autologous cell therapy for the treatment of heart failure. It also provides NKR-2, an autologous chimeric antigen receptor (CAR), a lab engineered receptor for the treatment of cancer. In addition, the company’s pre-clinical stage product candidates include NKp30, an activated receptor of NK cells; B7H6 therapies, which kills cancer cells; and CAR T-cell, an allogeneic T-cell platform. Further, it offers C-CATHez, a cell injection catheter; heart access sheaths; mitral valve neo-chordaes; and closure devices. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE